Drupal.behaviors.print = function(context) {window.print();window.close();}>
BG Medicine Q1 Revenues Fall but Galectin-3 Sales Jump as Company Pursues Expanded Use for Test
May 17, 2012
BG Medicine Q1 Revenues Fall but Galectin-3 Sales Jump as Company Pursues Expanded Use for Test
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
BG Medicine Says Data from 6,600-Patient Clinical Study Validates CardioScore Cardiac Risk Test
February 17, 2012 / ProteoMonitor
BG Medicine Files 510(k) for Automated Galectin-3 Test on Abbot Architect Platform
July 27, 2012 / ProteoMonitor
Abbott Receives EU CE Mark for Automated Version of BG Medicine's Galectin-3 Test
April 12, 2013 / ProteoMonitor
Lower CMS Payment Rate Could Affect Royalties, BG Medicine Says
March 26, 2013 / GenomeWeb Daily News
BG Medicine Goes Public, Begins Trading at $7 per Share
February 4, 2011 / ProteoMonitor